Click here to close now.




















Welcome!

News Feed Item

Global Genes Partners With SWAN USA To Help Undiagnosed Rare Disease Patients Seek A Medical Diagnosis Through Free Whole Exome Sequencing Program

Parabase Genomics and the UCLA Clinical Genomics Center Selected as Pilot Partners

ALISO VIEJO, Calif., Feb. 04, 2014 /PRNewswire-USNewswire/ -- Eight years. That's the average amount of time patients wait to receive an official medical diagnosis when facing a rare genetic disease. The stress this medical diagnostic process places on families can be devastating. This year, undiagnosed rare disease patients will receive a gift of hope through an innovative whole genome sequencing pilot program developed and funded by Global Genes in partnership with SWAN USA (Syndromes Without A Name).

The collaborative agreement between Global Genes and SWAN USA will allow undiagnosed rare disease patients who cannot afford costly genomic testing – which can range from $3,500 to more than $5,000 per test - to obtain free clinical genomic sequencing testing to aid in finding the genetic source of their mysterious illnesses.  Boston-based Parabase Genomics and the UCLA Clinical Genomics Center have been selected as the first clinical genomic sequencing providers for the pilot project. 

Starting March 1, 2014, approximately 30 undiagnosed patients will undergo free whole exome sequencing, funded by Global Genes through a donor directed fund launched last September at the 2nd Annual Tribute to Champions of Hope event. With additional funding underway, the program is expected to expand and include more undiagnosed patients.

"We are thrilled to be working with leading genomic sequencing providers on both coasts to help patients in our community find  diagnoses for their rare and genetic diseases," said Andrea Epstein, Executive Director, Global Genes. "We talk to patients, parent advocates and families every day who have had the misfortune of receiving up to three misdiagnoses and are facing diseases that have eluded medical professionals for years due to lack of access to the most cutting edge testing techniques."

Global Genes established a multi-disciplinary committee and a formal Request for Proposal process to select Parabase Genomics and UCLA's Clinical Genomics Center as the initial genomic sequencing partners for the pilot project. This committee reflected a diverse group of rare and genetic disease stakeholders including parent advocates, patient foundation leaders, clinical advisors and Global Genes executives.  The team included Amy Clugston, Founder of SWAN USA, Caroline Loewy, EVP and CFO Tobira Therapeutics and parent advocate, Cristy Spooner, parent advocate, Gary Jackson PhD, Genetics and Technology Consultant, Heather Long, Founder of U.R. Our Hope, Nicole Boice, President, Global Genes and Andrea Epstein, Executive Director, Global Genes.

Global Genes' partner on the project, SWAN USA, is equally enthusiastic about the potential effect on families that this genetic testing will bring.

"Families face an incredible emotional and economic hardship as they struggle to find a proper diagnosis for their loved ones disease," said Amy Clugston, Founder and President, SWAN USA. "To be a part of this innovative program and have the capacity to aid families locate the resources they need is exactly our goal."

Helping to make this technology a reality for undiagnosed patients is Boston-based Parabase Genomics and the UCLA Clinical Genomics Center based in Los Angeles.

"It's our pleasure to join this circle of passionate advocates and experts by providing a timely diagnosis to these deserving patients and their families," said Andy Bhattachariee, PhD, CEO and Scientific Director of Parabase.  "In 2014, we look forward to helping these families, and others, with our LifeTime RareDx Test.  One of the challenges with translation of next-generation sequencing to newborns and children is the long time it takes to get results.  We have developed a complete workflow from blood to a medical report in 2-4 weeks, and our plan is to shorten this timeline to a few days."

The UCLA Clinical Genomics Center also shared their enthusiasm as the West Coast sequencing provider in this new collaborative program. "We are honored and pleased to partner with Global Genes and SWAN USA to accelerate the diagnosis of those affected by rare and genetic diseases," added Dr. Stan Nelson, Professor, Department of Human Genetics, UCLA.

About Global Genes

Global Genes is a leading rare and genetic disease patient advocacy organization.  The organization mission is to 'Eliminate the Challenges of Rare Disease', by equipping patients to become successful advocates, and through education and empowerment, become 'activists' for their disease.  Global Genes does this through a growing portfolio of educational tools and resources, events, building out critical connections and funding innovations in science and technology that will impact patients within their lifetime.  Recognized worldwide by the Blue Denim Genes Ribbon™, Global Genes unites experts, advocates and patients of all ages to stand together in hope for treatments and cures for the estimated 7,000 rare and genetic diseases that impact approximately 30 million Americans and over 250 million people worldwide. For more information about Global Genes™, please visit the following links:

About SWAN USA

SWAN USA is a non-profit tax exempt organization that offers support, information and advice to families of children living with an undiagnosed condition – or a syndrome without a name. The organization offers support, advice and information on the challenges that families face when there is no diagnosis and advocates for changes in the medical community that will benefit undiagnosed individuals.  To learn more about SWAN USA, visit www.undiagnosed-usa.org.

About Parabase Genomics

Parabase Genomics is a privately held molecular diagnostics company focused on changing the way newborns and children with genetic disorders are diagnosed and treated. The Company's LifeTime Tests™ are the first commercially available services that provide a rapid non-invasive method for sample collection and diagnosis of genetic conditions using dried blood spots. This proprietary genetic and informational platform generates actionable information about a newborn's disease profile. Physicians can now avoid delays and adverse consequences by running one single test that is equivalent to several hundred parallel diagnostic tests commonly used today. To learn more, visit http://www.parabasegenomics.com.

About the UCLA Clinical Genomics Center

With expertise in Pediatrics, Human Genetics, and Pathology, the UCLA Clinical Genomics Center provides a comprehensive analysis and diagnostic interpretation of a patient's entire protein-encoding genome by searching through 37 million base pairs in 20,000 genes to potentially locate the single DNA change responsible for the patient's disorder. The Center, part of the David Geffen School of Medicine at UCLA, utilizes next generation sequencing technology, state-of-the-art computational and bioinformatic resources, and integrated laboratory information systems to deliver a precise genetic diagnosis for the benefit of patients and physicians. To learn more, visit: http://pathology.ucla.edu.

SOURCE Global Genes

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
"We've just seen a huge influx of new partners coming into our ecosystem, and partners building unique offerings on top of our API set," explained Seth Bostock, Chief Executive Officer at IndependenceIT, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Learn how you can use the CoSN SEND II Decision Tree for Education Technology to make sure that your K–12 technology initiatives create a more engaging learning experience that empowers students, teachers, and administrators alike.
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his session at 17th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Partnerships at Com...
SYS-CON Events announced today that VividCortex, the monitoring solution for the modern data system, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The database is the heart of most applications, but it’s also the part that’s hardest to scale, monitor, and optimize even as it’s growing 50% year over year. VividCortex is the first unified suite of database monitoring tools specifically desi...
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...
Digital Transformation is the ultimate goal of cloud computing and related initiatives. The phrase is certainly not a precise one, and as subject to hand-waving and distortion as any high-falutin' terminology in the world of information technology. Yet it is an excellent choice of words to describe what enterprise IT—and by extension, organizations in general—should be working to achieve. Digital Transformation means: handling all the data types being found and created in the organizat...
Chuck Piluso presented a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. Prior to Secure Infrastructure and Services, Mr. Piluso founded North American Telecommunication Corporation, a facilities-based Competitive Local Exchange Carrier licensed by the Public Service Commission in 10 states, serving as the company's chairman and president from 1997 to 2000. Between 1990 and 1997, Mr. Piluso served as chairman & founder of International Te...